Document is current
Any future updates will be listed below
-
Authors
Fabian, Kellsye P https://orcid.org/0000-0002-0273-5647
Padget, Michelle R
Fujii, Rika
Schlom, Jeffrey https://orcid.org/0000-0001-7932-4072
Hodge, James W https://orcid.org/0000-0001-5282-3154
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03493945 at ClinicalTrials.govDocuments that mention this clinical trial
582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2021-sitc2021.582
48 Interrogation of the peripheral immunome from QuEST1 in men with castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-sitc2025.0048
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
https://doi.org/10.1136/jitc-2020-001691
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003238
- License Information
